OBJECTIVES: The Ontario Drug Benefit (ODB) Formulary is the publicly funded provincial drug plan in Ontario. Drugs are included subsequent to a review of submitted clinical efficacy and pharmacoeconomic evidence by the Committee to Evaluate Drugs (CED). The objective of this analysis was to examine the degree to which economic evidence was utilized to inform drug reimbursement decision making in Ontario. METHODS: All publicly available CED “Recommendation and Rationale” documents were reviewed to classify type of economic evidence, CED recommendations and rationales.  Descriptiveand logistic regression analyses were conducted to examine the extent that economic evaluation impacts CED recommendations among other potential predictor factors. RESULTS: A total of 123 separate recommendations were retrieved (July 2007 to November 2012). Forty –seven percent received a fund recommendation while 53% received a do not fund recommendation. Almost all recommendations included some discussion of economic evidence; however complexity was limited to a discussion of price of therapy only for the majority (70%). Regression analysis found that documents including a discussion of economic evidence beyond price and statement of a price of therapy less than or similar to alternatives were more likely to result in positive recommendations (p < 0.05). CONCLUSIONS: Although economic evidence was routinely reviewed, discussion was usually limited to price of therapy. However, when pharmacoeconomic evidence beyond price alone was discussed, a  recommendation to fund by the CED was more likely.